{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:02:37Z","timestamp":1790866957344,"version":"4.1.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10787-025-01997-3","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:58:32Z","timestamp":1760003912000},"page":"6535-6553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["URAT1 and GLUT9 as drug targets in gout: progress in transporter-directed therapies and delivery technologies"],"prefix":"10.1007","volume":"33","author":[{"given":"Soumya","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9192-5265","authenticated-orcid":false,"given":"Ranjit K.","family":"Harwansh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupa","family":"Mazumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"issue":"19","key":"1997_CR1","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.3390\/molecules26195905","volume":"26","author":"S Adepu","year":"2021","unstructured":"Adepu S, Ramakrishna S (2021) Controlled drug delivery systems: current status and future directions. Molecules 26(19):5905. https:\/\/doi.org\/10.3390\/molecules26195905. (PMID:34641447;PMCID:PMC8512302)","journal-title":"Molecules"},{"key":"1997_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1124\/jpet.115.231647","volume":"357","author":"SO Ahn","year":"2016","unstructured":"Ahn SO, Ohtomo S, Kiyokawa J et al (2016) Stronger uricosuric effects of the novel selective URAT1 inhibitor UR-1102 lowered plasma urate in tufted capuchin monkeys to a greater extent than benzbromarone. J Pharmacol Exp Ther 357:157\u2013166","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1997_CR3","doi-asserted-by":"publisher","first-page":"102447","DOI":"10.1016\/j.omtn.2025.102447","volume":"36","author":"X Ai","year":"2025","unstructured":"Ai X, Ding S, Zhou S, Du F, Liu S, Cui X (2025) Enhancing RNA editing efficiency and specificity with engineered ADAR2 guide RNAs. Mol Ther Nucleic Acids 36(1):102447. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2162253125000010","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"1997_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-022-00625-y","volume":"23","author":"Z Ali","year":"2022","unstructured":"Ali Z, Din FU, Zahid F, Sohail S, Imran B, Khan S, Malik M, Zeb A, Khan GM (2022) Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout. BMC Pharmacol Toxicol 23(1):86. https:\/\/doi.org\/10.1186\/s40360-022-00625-y","journal-title":"BMC Pharmacol Toxicol"},{"key":"1997_CR5","doi-asserted-by":"crossref","unstructured":"Andaloussi SEL, Lakhal S, M\u00e4ger I, Wood MJA. Exosomes for targeted siRNA delivery across biological barriers. Adv Drug Deliv Rev [Internet]. 2013;65(3):391\u20137. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0169409X12002438","DOI":"10.1016\/j.addr.2012.08.008"},{"issue":"11","key":"1997_CR6","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1248\/bpb.b20-00597","volume":"43","author":"H Arakawa","year":"2020","unstructured":"Arakawa H, Amezawa N, Kawakatsu Y, Tamai I (2020) Renal reabsorptive transport of uric acid precursor xanthine by URAT1 and GLUT9. Biol Pharm Bull 43(11):1792\u20131798. https:\/\/doi.org\/10.1248\/bpb.b20-00597","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"1997_CR7","doi-asserted-by":"publisher","first-page":"630","DOI":"10.30574\/ijsra.2023.8.1.0103","volume":"8","author":"TR Athira","year":"2023","unstructured":"Athira TR, Selvaraju K, Gowrishankar NL (2023) Biodegradable polymeric nanoparticles: the novel carrier for controlled release drug delivery system. Int J Sci Res Arch 8(1):630\u2013637","journal-title":"Int J Sci Res Arch"},{"key":"1997_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-019-0080-x","volume":"59","author":"VF Azevedo","year":"2019","unstructured":"Azevedo VF, Kos IA, Vargas-Santos AB et al (2019) Benzbromarone in the treatment of gout. Adv Rheumatol 59:37. https:\/\/doi.org\/10.1186\/s42358-019-0080-x","journal-title":"Adv Rheumatol"},{"key":"1997_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/annrheumdis-2024-eular.4573","volume":"83","author":"C Bao","year":"2024","unstructured":"Bao C, Dai DH, Hu Q et al (2024) OP0129\/a 12-week, multicenter, randomized, double-blind, placebo-controlled, phase 2 study of ruzinurad (SHR4640) in combination with febuxostat for primary gout and hyperuricemia with an inadequate response to febuxostat alone. Ann Rheum Dis 83:86\u201387","journal-title":"Ann Rheum Dis"},{"key":"1997_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00160","volume":"5","author":"CL Benn","year":"2018","unstructured":"Benn CL, Dua P, Gurrell R, Loudon P, Pike A, Storer RI, Vangjeli C (2018) Physiology of hyperuricemia and urate-lowering treatments. Front Med 5:160. https:\/\/doi.org\/10.3389\/fmed.2018.00160","journal-title":"Front Med"},{"issue":"2","key":"1997_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020147","volume":"9","author":"E Bettini","year":"2021","unstructured":"Bettini E, Locci M (2021) SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond. Vaccines 9(2):147. https:\/\/doi.org\/10.3390\/vaccines9020147","journal-title":"Vaccines"},{"issue":"1","key":"1997_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4274\/tjps.galenos.2019.32656","volume":"18","author":"S Bhatt","year":"2021","unstructured":"Bhatt S, Sharma JB, Kamboj R, Kumar M, Saini V, Mandge S (2021) Design and optimization of Febuxostat-loaded nano lipid carriers using full factorial design. Turk J Pharm Sci 18(1):61\u201367. https:\/\/doi.org\/10.4274\/tjps.galenos.2019.32656","journal-title":"Turk J Pharm Sci"},{"issue":"6","key":"1997_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1053\/j.ackd.2012.07.009","volume":"19","author":"IA Bobulescu","year":"2012","unstructured":"Bobulescu IA, Moe OW (2012) Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis 19(6):358\u2013371. https:\/\/doi.org\/10.1053\/j.ackd.2012.07.009","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"1997_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics9020012","volume":"9","author":"U Bulbake","year":"2017","unstructured":"Bulbake U, Doppalapudi S, Kommineni N, Khan W (2017) Liposomal formulations in clinical use: an updated review. Pharmaceutics 9(2):12. https:\/\/doi.org\/10.3390\/pharmaceutics9020012","journal-title":"Pharmaceutics"},{"issue":"19","key":"1997_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914865","volume":"24","author":"R Cai","year":"2023","unstructured":"Cai R, Lv R, Shi X, Yang G, Jin J (2023) CRISPR\/dCas9 tools: epigenetic mechanism and application in gene transcriptional regulation. Int J Mol Sci 24(19):14865. https:\/\/doi.org\/10.3390\/ijms241914865","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1997_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2144\/btn-2018-0187","volume":"66","author":"CV Campenhout","year":"2019","unstructured":"Campenhout CV, Cabochette P, Veillard AC, Laczik M, Zelisko-Schmidt A, Sabatel C, Dhainaut M, Vanhollebeke B, Gueydan C, Kruys V (2019) Guidelines for optimized gene knockout using CRISPR\/Cas9. Biotechniques 66(6):295\u2013302. https:\/\/doi.org\/10.2144\/btn-2018-0187","journal-title":"Biotechniques"},{"issue":"4","key":"1997_CR17","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1534\/genetics.111.131433","volume":"188","author":"D Carroll","year":"2011","unstructured":"Carroll D (2011) Genome engineering with zinc-finger nucleases. Genetics 188(4):773\u2013782. https:\/\/doi.org\/10.1534\/genetics.111.131433","journal-title":"Genetics"},{"key":"1997_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/978-3-642-14541-4_6","volume":"201","author":"I Cascorbi","year":"2011","unstructured":"Cascorbi I (2011) P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 201:261\u2013283. https:\/\/doi.org\/10.1007\/978-3-642-14541-4_6. (PMID: 21103972)","journal-title":"Handb Exp Pharmacol"},{"key":"1997_CR19","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2025.10","volume":"27","author":"B Cetin","year":"2025","unstructured":"Cetin B, Erendor F, Eksi YE, Sanlioglu AD, Sanlioglu S (2025) Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects. Expert Rev Mol Med 27:e16. https:\/\/doi.org\/10.1017\/erm.2025.10","journal-title":"Expert Rev Mol Med"},{"issue":"6","key":"1997_CR20","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10059-009-0093-0","volume":"27","author":"CII Chang","year":"2009","unstructured":"Chang CII, Kang HS, Ban C, Kim S, Lee Dk (2009) Dual-Target gene silencing by using long, synthetic sirna duplexes without triggering antiviral responses. Mol Cells 27(6):689\u201396. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1016847823136971","journal-title":"Mol Cells"},{"issue":"3","key":"1997_CR21","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/2472555220949501","volume":"26","author":"Y Chen","year":"2021","unstructured":"Chen Y, Zhao Z, Li Y, Li L, Jiang Y, Cao Y, Zhou P, Wu T, Pang J (2021) Characterizations of the urate transporter, GLUT9, and its potent inhibitors by patch-clamp technique. SLAS Discov 26(3):450\u2013459. https:\/\/doi.org\/10.1177\/2472555220949501","journal-title":"SLAS Discov"},{"key":"1997_CR22","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s10753-018-0948-7","volume":"42","author":"K Cheng","year":"2019","unstructured":"Cheng K, Song Z, Chen Y, Li S, Zhang Y, Zhang H, Zhang L, Wang C, Wang T (2019) Resveratrol protects against renal damage via attenuation of inflammation and oxidative stress in high-fat-diet-induced obese mice. Inflammation 42:937\u2013945","journal-title":"Inflammation"},{"key":"1997_CR23","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1038\/s41467-024-47805-4","volume":"15","author":"C Cho","year":"2024","unstructured":"Cho C, Kim B, Kim DS et al (2024) Large-scale cross-ancestry genome-wide meta-analysis of serum urate. Nat Commun 15:3441. https:\/\/doi.org\/10.1038\/s41467-024-47805-4","journal-title":"Nat Commun"},{"issue":"1","key":"1997_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5049\/EBP.2021.19.1.1","volume":"19","author":"S Chung","year":"2021","unstructured":"Chung S, Kim GH (2021) Urate transporters in the kidney: what clinicians need to know. Electrolyte Blood Press 19(1):1\u20139. https:\/\/doi.org\/10.5049\/EBP.2021.19.1.1","journal-title":"Electrolyte Blood Press"},{"issue":"2","key":"1997_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000512178","volume":"30","author":"AFG Cicero","year":"2021","unstructured":"Cicero AFG, Fogacci F, Cincione RI, Tocci G, Borghi C (2021) Clinical effects of xanthine oxidase inhibitors in hyperuricemic patients. Med Princ Pract 30(2):122\u2013130","journal-title":"Med Princ Pract"},{"issue":"6","key":"1997_CR26","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.3390\/jcm9062004","volume":"9","author":"K Dhuri","year":"2020","unstructured":"Dhuri K, Bechtold C, Quijano E, Pham H, Gupta A, Vikram A, Bahal R (2020) Antisense Oligonucleotides: an emerging area in drug discovery and development. J Clin Med 9(6):2004. https:\/\/doi.org\/10.3390\/jcm9062004. (PMID:32604776;PMCID:PMC7355792)","journal-title":"J Clin Med"},{"key":"1997_CR27","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1080\/15257770.2011.603711","volume":"30","author":"M Doshi","year":"2011","unstructured":"Doshi M, Takiue Y, Saito H, Hosoyamada M (2011) The increased protein level of URAT1 was observed in obesity\/metabolic syndrome model mice. Nucleosides Nucleotides Nucleic Acids 30:1290\u20131294","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"5","key":"1997_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.61186\/ibj.27.5.219","volume":"27","author":"S Ebrahimi","year":"2023","unstructured":"Ebrahimi S, Khosravi MA, Raz A, Karimipoor M, Parvizi P (2023) CRISPR-Cas technology as a revolutionary genome editing tool: mechanisms and biomedical applications. Iran Biomed J 27(5):219\u2013246. https:\/\/doi.org\/10.61186\/ibj.27.5.219","journal-title":"Iran Biomed J"},{"issue":"3","key":"1997_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17030375","volume":"17","author":"M El-Tanani","year":"2025","unstructured":"El-Tanani M, Satyam SM, Rabbani SA, El-Tanani Y, Aljabali AAA, Al Faouri I, Rehman A (2025) Revolutionizing drug delivery: the impact of advanced materials science and technology on precision medicine. Pharmaceutics 17(3):375. https:\/\/doi.org\/10.3390\/pharmaceutics17030375","journal-title":"Pharmaceutics"},{"issue":"6","key":"1997_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.semnephrol.2020.12.006","volume":"40","author":"C Estiverne","year":"2020","unstructured":"Estiverne C, Mandal AK, Mount DB (2020) Molecular pathophysiology of uric acid homeostasis. Semin Nephrol 40(6):535\u2013549. https:\/\/doi.org\/10.1016\/j.semnephrol.2020.12.006","journal-title":"Semin Nephrol"},{"issue":"12","key":"1997_CR31","doi-asserted-by":"publisher","first-page":"5302","DOI":"10.1210\/en.2009-0747","volume":"150","author":"SA Evans","year":"2009","unstructured":"Evans SA, Doblado M, Chi MM, Corbett JA, Moley KH (2009) Facilitative glucose transporter 9 expression affects glucose sensing in pancreatic beta-cells. Endocrinology 150(12):5302\u20135310. https:\/\/doi.org\/10.1210\/en.2009-0747","journal-title":"Endocrinology"},{"key":"1997_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-642-03103-8_1","volume":"50","author":"MR Fabian","year":"2010","unstructured":"Fabian MR, Sundermeier TR, Sonenberg N (2010) Understanding how miRNAs post-transcriptionally regulate gene expression. Prog Mol Subcell Biol 50:1\u201320. https:\/\/doi.org\/10.1007\/978-3-642-03103-8_1. (PMID: 19841878)","journal-title":"Prog Mol Subcell Biol"},{"key":"1997_CR33","doi-asserted-by":"crossref","unstructured":"Facchini F, Chen YD, Hollenbeck CB, Reaven GM Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991, 266, 3008\u20133011. [CrossRef] [PubMed]","DOI":"10.1001\/jama.1991.03470210076036"},{"issue":"3","key":"1997_CR34","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.23582","volume":"14","author":"M Freilich","year":"2022","unstructured":"Freilich M, Arredondo A, Zonnoor SL, McFarlane IM (2022) Elevated serum uric acid and cardiovascular disease: a review and potential therapeutic interventions. Cureus 14(3):e23582. https:\/\/doi.org\/10.7759\/cureus.23582. (PMID:35494989;PMCID:PMC9045796)","journal-title":"Cureus"},{"key":"1997_CR35","unstructured":"George C, Leslie SW, Minter DA (2025) Hyperuricemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459218\/"},{"issue":"5","key":"1997_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010682","volume":"5","author":"N Gupta","year":"2010","unstructured":"Gupta N, Fisker N, Asselin MC, Lindholm M, Rosenbohm C, \u00d8rum H, Elm\u00e9n J, Seidah NG, Straarup EM (2010) A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS ONE 5(5):e10682. https:\/\/doi.org\/10.1371\/journal.pone.0010682","journal-title":"PLoS ONE"},{"key":"1997_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02558-3","author":"SK Hart","year":"2025","unstructured":"Hart SK, M\u00fcller S, Wessels HH et al (2025) Precise RNA targeting with CRISPR\u2013Cas13d. Nat Biotechnol. https:\/\/doi.org\/10.1038\/s41587-025-02558-3","journal-title":"Nat Biotechnol"},{"issue":"14","key":"1997_CR38","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.1093\/nar\/gkw533","volume":"44","author":"MA Havens","year":"2016","unstructured":"Havens MA, Hastings ML (2016) Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res 44(14):6549\u20136563. https:\/\/doi.org\/10.1093\/nar\/gkw533","journal-title":"Nucleic Acids Res"},{"key":"1997_CR39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/978-1-4939-2687-9_23","volume":"1311","author":"JS Hawkins","year":"2015","unstructured":"Hawkins JS, Wong S, Peters JM, Almeida R, Qi LS (2015) Targeted transcriptional repression in bacteria using CRISPR interference (CRISPRi). Methods Mol Biol 1311:349\u2013362. https:\/\/doi.org\/10.1007\/978-1-4939-2687-9_23. (PMID:25981485;PMCID:PMC4845913)","journal-title":"Methods Mol Biol"},{"issue":"10","key":"1997_CR40","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/membranes1110073","volume":"11","author":"Y He","year":"2021","unstructured":"He Y, He G, He T (2021) Specifically targeted transport of plasma membrane transporters: from potential mechanisms for regulating cell health or disease to applications. Membranes (Basel) 11(10):736. https:\/\/doi.org\/10.3390\/membranes1110073. (PMID:34677502;PMCID:PMC8538571)","journal-title":"Membranes (Basel)"},{"issue":"1","key":"1997_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31833-4","volume":"8","author":"P Heitel","year":"2018","unstructured":"Heitel P, Gellrich L, Heering J, Goebel T, Kahnt A, Proschak E, Schubert-Zsilavecz M, Merk D (2018) Urate transporter inhibitor lesinurad is a selective peroxisome proliferator-activated receptor gamma modulator (sPPAR\u03b3M) in vitro. Sci Rep 8(1):13554. https:\/\/doi.org\/10.1038\/s41598-018-31833-4","journal-title":"Sci Rep"},{"key":"1997_CR42","first-page":"1882","volume":"34","author":"J Hjortnaes","year":"2007","unstructured":"Hjortnaes J, Algra A, Olijhoek J, Huisman M, Jacobs J, van der Graaf Y, Visseren F (2007) Serum uric acid levels and risk for vascular diseases in patients with metabolic syndrome. J Rheumatol 34:1882\u20131887","journal-title":"J Rheumatol"},{"key":"1997_CR43","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R et al (2021) Lipid nanoparticles for mrna delivery. Nat Rev Mater 6:1078\u20131094. https:\/\/doi.org\/10.1038\/s41578-021-00358-0","journal-title":"Nat Rev Mater"},{"key":"1997_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6113","author":"X Hu","year":"2024","unstructured":"Hu X, Lin H, Huang Y et al (2024) Effect of hepatic impairment on the pharma- cokinetics and pharmacodynamics of SHR4640, a selective human urate transporter 1 inhibitor. J Clin Pharmacol. https:\/\/doi.org\/10.1002\/jcph.6113","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1997_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/colloids1010001","volume":"1","author":"A Ihnatsyeu-Kachan","year":"2017","unstructured":"Ihnatsyeu-Kachan A, Dzmitruk V, Apartsin E, Krasheninina O, Ionov M, Loznikova S et al (2017) Multi-target inhibition of cancer cell growth by SiRNA cocktails and 5-fluorouracil using effective piperidine-terminated phosphorus dendrimers. Coll Interfaces 1(1):1\u201318","journal-title":"Coll Interfaces"},{"issue":"1","key":"1997_CR46","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-021-02182-9","volume":"23","author":"M Jagia","year":"2021","unstructured":"Jagia M, Kale DP, Bansal AK, Patel S (2021) Novel co-crystals and eutectics of Febuxostat: characterization, mechanism of formation, and improved dissolution. AAPS PharmSciTech 23(1):43. https:\/\/doi.org\/10.1208\/s12249-021-02182-9","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"1997_CR47","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5281\/zenodo.14640610","volume":"1","author":"A Jain","year":"2024","unstructured":"Jain A, Parihar DK, Tiwary B, Kushwaha M (2024) Evaluation of antibacterial activity of silver nanoparticle loaded Curcuma extract collected from Sarguja district of Chhattisgarh. Prob Sci 1(2):58\u201364. https:\/\/doi.org\/10.5281\/zenodo.14640610","journal-title":"Prob Sci"},{"issue":"11","key":"1997_CR48","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3390\/antiox9111092","volume":"9","author":"K Jakubczyk","year":"2020","unstructured":"Jakubczyk K, Dru\u017cga A, Katarzyna J, Skonieczna-\u017bydecka K (2020) Antioxidant potential of curcumin-A meta-analysis of randomized clinical trials. Antioxidants (Basel) 9(11):1092. https:\/\/doi.org\/10.3390\/antiox9111092. (PMID:33172016;PMCID:PMC7694612)","journal-title":"Antioxidants (Basel)"},{"key":"1997_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.925219","volume":"13","author":"C Jenkins","year":"2022","unstructured":"Jenkins C, Hwang JH, Kopp JB et al (2022) Review of urate-lowering therapeutics: from the past to the future. Front Pharmacol 13:925219","journal-title":"Front Pharmacol"},{"issue":"13","key":"1997_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.925219","volume":"23","author":"C Jenkins","year":"2022","unstructured":"Jenkins C, Hwang JH, Kopp JB, Winkler CA, Cho SK (2022) Review of urate-lowering therapeutics: from the past to the future. Front Pharmacol 23(13):925219. https:\/\/doi.org\/10.3389\/fphar.2022.925219. (PMID:36081938;PMCID:PMC9445164)","journal-title":"Front Pharmacol"},{"issue":"4","key":"1997_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/biom15040511","volume":"15","author":"LP Jones","year":"2025","unstructured":"Jones LP, Martin DE, Murray J, Sancilio F, Tripp RA (2025) Probenecid inhibits NLRP3 inflammasome activity and mitogen-activated protein kinases (MAPKs). Biomolecules 15(4):511. https:\/\/doi.org\/10.3390\/biom15040511","journal-title":"Biomolecules"},{"key":"1997_CR52","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.2147\/DDDT.S474398","volume":"19","author":"P Jutabha","year":"2025","unstructured":"Jutabha P, Kumar V, Anzai N, Rice PJ, Lightner JW, Endou H et al (2025) Benzbromarone analog SAR: potent hURAT1 (SLC22A12) inhibitors and drug transporter interaction studies. Drug des Devel Ther 19:1377\u20131392","journal-title":"Drug des Devel Ther"},{"issue":"4","key":"1997_CR53","first-page":"659","volume":"66","author":"Y Kanai","year":"2008","unstructured":"Kanai Y (2008) Molecular mechanisms of urate transport in renal tubules: localization and function of urate transporters. Nihon Rinsho 66(4):659\u2013666 (Japanese. PMID: 18409511)","journal-title":"Nihon Rinsho"},{"issue":"9","key":"1997_CR54","doi-asserted-by":"publisher","first-page":"e1332","DOI":"10.34067\/KID.0000000000000221","volume":"4","author":"V Kannuthurai","year":"2023","unstructured":"Kannuthurai V, Gaffo A (2023) Management of patients with gout and kidney disease: a review of available therapies and common missteps. Kidney360 4(9):e1332\u2013e1340. https:\/\/doi.org\/10.34067\/KID.0000000000000221","journal-title":"Kidney360"},{"issue":"7","key":"1997_CR55","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00467-004-1424-1","volume":"19","author":"F Komoda","year":"2004","unstructured":"Komoda F, Sekine T, Inatomi J, Enomoto A, Endou H, Ota T, Matsuyama T, Ogata T, Ikeda M, Awazu M, Muroya K, Kamimaki I, Igarashi T (2004) The W258X mutation in SLC22A12 is the predominant cause of Japanese renal hypouricemia. Pediatr Nephrol 19(7):728\u2013733. https:\/\/doi.org\/10.1007\/s00467-004-1424-1","journal-title":"Pediatr Nephrol"},{"key":"1997_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2019.102077","volume":"21","author":"R Krzyszto\u0144","year":"2019","unstructured":"Krzyszto\u0144 R, Wosch\u00e9e D, Reiser A, Schwake G, Strey HH, R\u00e4dler JO (2019) Single-cell kinetics of siRNA-mediated mRNA degradation. Nanomedicine 21:102077. https:\/\/doi.org\/10.1016\/j.nano.2019.102077","journal-title":"Nanomedicine"},{"issue":"2","key":"1997_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5281\/zenodo.13767525","volume":"1","author":"MK Kumar","year":"2024","unstructured":"Kumar MK, Ahirwar K, Mishra S (2024) Recent advancement in drug development for intranasal drug delivery system. Prob Sci 1(2):1\u201319. https:\/\/doi.org\/10.5281\/zenodo.13767525","journal-title":"Prob Sci"},{"issue":"Suppl 1","key":"1997_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10157-019-01811-9","volume":"24","author":"S Kuriyama","year":"2020","unstructured":"Kuriyama S (2020) Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia. Clin Exp Nephrol 24(Suppl 1):1\u20135. https:\/\/doi.org\/10.1007\/s10157-019-01811-9","journal-title":"Clin Exp Nephrol"},{"key":"1997_CR59","first-page":"1976","volume":"58","author":"HA Lee","year":"2019","unstructured":"Lee HA, Yu KS, Park SI et al (2019) URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers. Rheumatology (Oxford) 58:1976\u20131984","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1997_CR60","doi-asserted-by":"publisher","first-page":"903","DOI":"10.7150\/ijms.101219.PMID:39991772;PMCID:PMC11843151","volume":"22","author":"CL Lee","year":"2025","unstructured":"Lee CL, Chuang CK, Chiu HC, Chang YH, Tu YR, Lo YT, Lin HY, Lin SP (2025) Understanding genetic screening: harnessing health information to prevent disease risks. Int J Med Sci 22(4):903\u2013919. https:\/\/doi.org\/10.7150\/ijms.101219.PMID:39991772;PMCID:PMC11843151","journal-title":"Int J Med Sci"},{"key":"1997_CR61","doi-asserted-by":"publisher","first-page":"104200","DOI":"10.1016\/j.jddst.2023.104200","volume":"80","author":"F Lei","year":"2023","unstructured":"Lei F, Li P, Chen T, Wang Q, Wang C, Liu Y (2023) Recent advances in curcumin-loaded biomimetic nanomedicines for targeted therapies. J Drug Deliv Sci Technol 80:104200. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1773224723000527","journal-title":"J Drug Deliv Sci Technol"},{"key":"1997_CR62","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ijpharm.2019.03.013","volume":"562","author":"WB Liechty","year":"2019","unstructured":"Liechty WB, Scheuerle RL, Vela Ramirez JE, Peppas NA (2019) Cytoplasmic delivery of functional siRNA using ph-responsive nanoscale hydrogels. Int J Pharm 562:249\u2013257. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.03.013","journal-title":"Int J Pharm"},{"issue":"8","key":"1997_CR63","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrd4626","volume":"14","author":"L Lin","year":"2015","unstructured":"Lin L, Yee SW, Kim RB, Giacomini KM (2015) Slc transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov 14(8):543\u2013560. https:\/\/doi.org\/10.1038\/nrd4626","journal-title":"Nat Rev Drug Discov"},{"key":"1997_CR64","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1093\/rheumatology\/keab198","volume":"60","author":"Y Lin","year":"2021","unstructured":"Lin Y, Chen X, Ding H et al (2021) Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study. Rheumatology (Oxford) 60:5089\u20135097","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1997_CR65","doi-asserted-by":"publisher","first-page":"508","DOI":"10.33594\/000000154","volume":"53","author":"BP L\u00fcscher","year":"2019","unstructured":"L\u00fcscher BP, Surbek DV, Cl\u00e9men\u00e7on B, Huang X, Albrecht C, Marini C, Hediger MA, Baumann MU (2019) Different pharmacological properties of GLUT9a and GLUT9b: potential implications in preeclampsia. Cell Physiol Biochem 53(3):508\u2013517. https:\/\/doi.org\/10.33594\/000000154","journal-title":"Cell Physiol Biochem"},{"issue":"4","key":"1997_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/cells11040633","volume":"11","author":"BP L\u00fcscher","year":"2022","unstructured":"L\u00fcscher BP, Albrecht C, Stieger B, Surbek DV, Baumann MU (2022) Glucose transporter 9 (GLUT9) plays an important role in the placental uric acid transport system. Cells 11(4):633. https:\/\/doi.org\/10.3390\/cells11040633","journal-title":"Cells"},{"issue":"3","key":"1997_CR67","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4103\/0975-7406.130965","volume":"6","author":"K Madaan","year":"2014","unstructured":"Madaan K, Kumar S, Poonia N, Lather V, Pandita D (2014) Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci 6(3):139\u2013150. https:\/\/doi.org\/10.4103\/0975-7406.130965","journal-title":"J Pharm Bioallied Sci"},{"issue":"4","key":"1997_CR68","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s10157-015-1186-z","volume":"20","author":"A Mancikova","year":"2016","unstructured":"Mancikova A, Krylov V, Hurba O, Sebesta I, Nakamura M, Ichida K, Stiburkova B (2016) Functional analysis of novel allelic variants in URAT1 and GLUT9 causing renal hypouricemia type 1 and 2. Clin Exp Nephrol 20(4):578\u2013584. https:\/\/doi.org\/10.1007\/s10157-015-1186-z","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"1997_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115514","volume":"44","author":"D Matsushita","year":"2025","unstructured":"Matsushita D, Toyoda Y, Lee Y, Aoi M, Matsuo H, Takada T, Nishizawa T (2025) Structural basis of urate transport by glucose transporter 9. Cell Rep 44(4):115514. https:\/\/doi.org\/10.1016\/j.celrep.2025.115514","journal-title":"Cell Rep"},{"key":"1997_CR70","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00011-009-0031-9","volume":"58","author":"Z Miao","year":"2009","unstructured":"Miao Z, Yan S, Wang J, Wang B, Li Y, Xing X, Yuan Y, Meng D, Wang L, Gu J (2009) Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions. Inflamm Res 58:659\u2013668","journal-title":"Inflamm Res"},{"issue":"12","key":"1997_CR71","doi-asserted-by":"publisher","first-page":"9865","DOI":"10.1007\/s11033-020-05977-4","volume":"47","author":"M Mihevc","year":"2020","unstructured":"Mihevc M, Petreski T, Maver U, Bevc S (2020) Renal proximal tubular epithelial cells: review of isolation, characterization, and culturing techniques. Mol Biol Rep 47(12):9865\u20139882. https:\/\/doi.org\/10.1007\/s11033-020-05977-4","journal-title":"Mol Biol Rep"},{"key":"1997_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00518","volume":"7","author":"H Miyata","year":"2016","unstructured":"Miyata H, Takada T, Toyoda Y, Matsuo H, Ichida K, Suzuki H (2016) Identification of febuxostat as a new strong ABCG2 inhibitor: potential applications and risks in clinical situations. Front Pharmacol 7:518. https:\/\/doi.org\/10.3389\/fphar.2016.00518","journal-title":"Front Pharmacol"},{"key":"1997_CR73","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12883-025-04241-1","volume":"25","author":"A Modiri","year":"2025","unstructured":"Modiri A, Hosseini L, Abolhasanpour N et al (2025) Mitotherapy in Alzheimer\u2019s and Parkinson\u2019s diseases: a systematic review of preclinical studies. BMC Neurol 25:227. https:\/\/doi.org\/10.1186\/s12883-025-04241-1","journal-title":"BMC Neurol"},{"issue":"3","key":"1997_CR74","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.5958\/0974-360X.2019.00245.2","volume":"12","author":"S Mohanty","year":"2019","unstructured":"Mohanty S, Panda S, Purohit D, Si SC (2019) A comprehensive review on PLGA - based nanoparticles used for rheumatoid arthritis. Res J Pharm Technol 12(3):1481\u20131488","journal-title":"Res J Pharm Technol"},{"issue":"10","key":"1997_CR75","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.tibtech.2019.03.008","volume":"37","author":"KA Molla","year":"2019","unstructured":"Molla KA, Yang Y (2019) CRISPR\/Cas-Mediated base editing: technical considerations and practical applications. Trends Biotechnol 37(10):1121\u201342. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0167779919300538","journal-title":"Trends Biotechnol"},{"issue":"4","key":"1997_CR76","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso MF, Tomkowicz B, Perry WL, Strohl WR (2017) Adeno-Associated Virus (AAV) as a vector for gene therapy. BioDrugs 31(4):317\u2013334. https:\/\/doi.org\/10.1007\/s40259-017-0234-5. (PMID: 28669112; PMCID: PMC5548848)","journal-title":"BioDrugs"},{"issue":"1","key":"1997_CR77","doi-asserted-by":"publisher","first-page":"F173","DOI":"10.1152\/ajprenal.00462.2018","volume":"316","author":"A Novikov","year":"2019","unstructured":"Novikov A, Fu Y, Huang W, Freeman B, Patel R, van Ginkel C, Koepsell H, Busslinger M, Onishi A, Nespoux J, Vallon V (2019) SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1. Am J Physiol Renal Physiol 316(1):F173\u2013F185. https:\/\/doi.org\/10.1152\/ajprenal.00462.2018","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"1997_CR78","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2174\/1381612826666200728144605","volume":"27","author":"IE Orhan","year":"2021","unstructured":"Orhan IE, Deniz FSS (2021) Natural products and extracts as Xantine oxidase inhibitors - a hope for gout disease? Curr Pharm des 27(2):143\u2013158. https:\/\/doi.org\/10.2174\/1381612826666200728144605","journal-title":"Curr Pharm des"},{"key":"1997_CR79","unstructured":"Padda IS, Mahtani AU, Patel P (2025) Small Interfering RNA (siRNA) Therapy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK580472\/"},{"issue":"1","key":"1997_CR80","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5455\/njppp.2012.v2.i1.3","volume":"2","author":"A Pandey","year":"2012","unstructured":"Pandey A, Chaturvedi M, Prakash H, Meena D (2012) Febuxostat - a new treatment for hyperuricaemia in gout - a review article. Natl J Physiol Pharm Pharmacol 2(1):23\u201328","journal-title":"Natl J Physiol Pharm Pharmacol"},{"issue":"8","key":"1997_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082510","volume":"9","author":"K Pavelcova","year":"2020","unstructured":"Pavelcova K, Bohata J, Pavlikova M, Bubenikova E, Pavelka K, Stiburkova B (2020a) Evaluation of the influence of genetic variants of SLC2A9 (GLUT9) and SLC22A12 (URAT1) on the development of hyperuricemia and gout. J Clin Med 9(8):2510. https:\/\/doi.org\/10.3390\/jcm9082510","journal-title":"J Clin Med"},{"issue":"8","key":"1997_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9082510","volume":"9","author":"K Pavelcova","year":"2020","unstructured":"Pavelcova K, Bohata J, Pavlikova M, Bubenikova E, Pavelka K, Stiburkova B (2020b) Evaluation of the influence of genetic variants of slc2a9 (Glut9) and slc22a12 (urat1) on the development of hyperuricemia and gout. J Clin Med 9(8):1\u201321","journal-title":"J Clin Med"},{"key":"1997_CR83","doi-asserted-by":"publisher","first-page":"A47","DOI":"10.1136\/annrheumdis-2018-EWRR2019.95","volume":"78","author":"K Pavelcova","year":"2019","unstructured":"Pavelcova K, Bohata J, Pavelka K, Stiburkova B (2019) P107 Polymorphisms in SLC2A9 and SLC22A12 genes are related to hyperuricemia, gout and also to hypouricemia. Ann Rheum Dis 78:A47. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0003496724081561","journal-title":"Ann Rheum Dis"},{"key":"1997_CR84","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212581","volume":"8","author":"F P\u00e9rez-Ruiz","year":"2019","unstructured":"P\u00e9rez-Ruiz F, Jansen T, Tausche AK, Ju\u00e1rez-Campo M, Gurunath RK, Richette P (2019) Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout. Drugs Context 8:212581. https:\/\/doi.org\/10.7573\/dic.212581","journal-title":"Drugs Context"},{"issue":"36","key":"1997_CR85","doi-asserted-by":"publisher","first-page":"15501","DOI":"10.1073\/pnas.0904411106","volume":"106","author":"F Preitner","year":"2009","unstructured":"Preitner F, Bonny O, Laverri\u00e8re A, Rotman S, Firsov D, Da Costa A et al (2009) Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc Natl Acad Sci U S A 106(36):15501\u201315506","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1997_CR86","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3899\/jrheum.121301","volume":"40","author":"K Pui","year":"2013","unstructured":"Pui K, Gow PJ, Dalbeth N (2013) Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol 40(6):872\u2013876","journal-title":"J Rheumatol"},{"key":"1997_CR87","doi-asserted-by":"publisher","first-page":"124734","DOI":"10.1016\/j.ijpharm.2024.124734","volume":"666","author":"MA Raza","year":"2024","unstructured":"Raza MA, Sharma MK, Nagori K, Jain P, Ghosh V, Gupta U et al (2024) Recent trends on polycaprolactone as sustainable polymer-based drug delivery system in the treatment of cancer: Biomedical applications and nanomedicine. Int J Pharm [internet] 666:124734","journal-title":"Int J Pharm [internet]"},{"issue":"19","key":"1997_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202207512","volume":"10","author":"DK Sahel","year":"2023","unstructured":"Sahel DK, Vora LK, Saraswat A, Sharma S, Monpara J, D\u2019Souza AA, Mishra D, Tryphena KP, Kawakita S, Khan S, Azhar M, Khatri DK, Patel K, Singh Thakur RR (2023) CRISPR\/Cas9 genome editing for tissue-specific in vivo targeting: nanomaterials and translational perspective. Adv Sci 10(19):e2207512. https:\/\/doi.org\/10.1002\/advs.202207512","journal-title":"Adv Sci"},{"key":"1997_CR89","doi-asserted-by":"publisher","first-page":"125106","DOI":"10.1016\/j.ijpharm.2024.125106","volume":"670","author":"N Sahu","year":"2025","unstructured":"Sahu N, Jain P, Sahu D, Kaur K, Nagori K, Ajazuddin (2025) Recent trends in the treatment of vitiligo using novel drug delivery system. Int J Pharm 670:125106","journal-title":"Int J Pharm"},{"key":"1997_CR90","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/963217","volume":"2013","author":"JF Saldanha","year":"2013","unstructured":"Saldanha JF, Leal VO, Stenvinkel P, Carraro-Eduardo JC, Mafra D (2013) Resveratrol: why is it a promising therapy for chronic kidney disease patients? Oxid Med Cell Longev 2013:963217","journal-title":"Oxid Med Cell Longev"},{"issue":"9","key":"1997_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105189","volume":"299","author":"M Sekine","year":"2023","unstructured":"Sekine M, Okamoto K, Pai EF, Nagata K, Ichida K, Hille R, Nishino T (2023) Allopurinol and oxypurinol differ in their strength and mechanisms of inhibition of xanthine oxidoreductase. J Biol Chem 299(9):105189. https:\/\/doi.org\/10.1016\/j.jbc.2023.105189","journal-title":"J Biol Chem"},{"key":"1997_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174291","volume":"907","author":"D Song","year":"2021","unstructured":"Song D, Zhao X, Wang F, Wang G (2021) A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: current therapeutic options and potential applications. Eur J Pharmacol 907:174291. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174291","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"1997_CR93","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.ymgme.2010.12.016","volume":"102","author":"B Stiburkova","year":"2011","unstructured":"Stiburkova B, Ichida K, Sebesta I (2011) Novel homozygous insertion in SLC2A9 gene caused renal hypouricemia. Mol Genet Metab 102(4):430\u2013435. https:\/\/doi.org\/10.1016\/j.ymgme.2010.12.016","journal-title":"Mol Genet Metab"},{"key":"1997_CR94","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.11.612563","author":"Y Suo","year":"2024","unstructured":"Suo Y, Fedor JG, Zhang H, Tsolova K, Shi X, Sharma K, Kumari S, Borgnia M, Zhan P, Im W, Lee SY (2024) Molecular basis of the urate transporter URAT1 inhibition by gout drugs. bioRxiv. https:\/\/doi.org\/10.1101\/2024.09.11.612563","journal-title":"bioRxiv."},{"key":"1997_CR95","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S0026-0495(97)90210-9","volume":"46","author":"S Takahashi","year":"1997","unstructured":"Takahashi S, Yamamoto T, Tsutsumi Z, Moriwaki Y, Yamakita J, Higashino K (1997) Close correlation between visceral fat accumulation and uric acid metabolism in healthy men. Metabolism 46:1162\u20131165","journal-title":"Metabolism"},{"issue":"16","key":"1997_CR96","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","volume":"76","author":"Y Takano","year":"2005","unstructured":"Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S (2005) Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase. Life Sci 76(16):1835\u201347. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0024320504010598","journal-title":"Life Sci"},{"issue":"1","key":"1997_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00706-7","volume":"7","author":"PK Tan","year":"2017","unstructured":"Tan PK, Liu S, Gunic E, Miner JN (2017) Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. Sci Rep 7(1):665. https:\/\/doi.org\/10.1038\/s41598-017-00706-7","journal-title":"Sci Rep"},{"issue":"Suppl 2","key":"1997_CR98","doi-asserted-by":"publisher","first-page":"780LP","DOI":"10.1136\/annrheumdis-2014-eular.4476","volume":"73","author":"PK Tan","year":"2014","unstructured":"Tan PK, Hyndman D, Miner JN (2014) SAT0521 Lesinurad, an inhibitor of the uric acid transporter urat1 and a potential therapy for gout, requires urat1 phenylalanine 365 for high affinity inhibition. Ann Rheum Dis 73(Suppl 2):780 LP\u2013780. Available from: http:\/\/ard.bmj.com\/content\/73\/Suppl_2\/780.1.abstract","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1997_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02228-z","volume":"21","author":"J Tang","year":"2023","unstructured":"Tang J, Li T, Xiong X, Yang Q, Su Z, Zheng M, Chen Q (2023) Colchicine delivered by a novel nanoparticle platform alleviates atherosclerosis by targeted inhibition of NF-\u03baB\/NLRP3 pathways in inflammatory endothelial cells. J Nanobiotechnol 21(1):460. https:\/\/doi.org\/10.1186\/s12951-023-02228-z","journal-title":"J Nanobiotechnol"},{"key":"1997_CR100","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.phrs.2016.12.029","volume":"117","author":"G Thiel","year":"2017","unstructured":"Thiel G, R\u00f6ssler OG (2017) Resveratrol regulates gene transcription via activation of stimulus-responsive transcription factors. Pharmacol Res 117:166\u2013176","journal-title":"Pharmacol Res"},{"key":"1997_CR101","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/978-1-4939-9220-1_15","volume":"1974","author":"C Tortiglione","year":"2019","unstructured":"Tortiglione C, de la Fuente JM (2019) synthesis of gold nanoparticles for gene silencing. Methods Mol Biol 1974:203\u2013214. https:\/\/doi.org\/10.1007\/978-1-4939-9220-1_15. (PMID: 31099005)","journal-title":"Methods Mol Biol"},{"issue":"3","key":"1997_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/nu14030575","volume":"14","author":"Y Toyoda","year":"2022","unstructured":"Toyoda Y, Takada T, Saito H, Hirata H, Ota-Kontani A, Tsuchiya Y, Suzuki H (2022) Identification of inhibitory activities of dietary flavonoids against URAT1, a renal urate re-absorber. In vitro screening and fractional approach focused on rooibos leaves. Nutrients 14(3):575. https:\/\/doi.org\/10.3390\/nu14030575","journal-title":"Nutrients"},{"issue":"September","key":"1997_CR103","first-page":"1","volume":"11","author":"P Ubanako","year":"2024","unstructured":"Ubanako P, Mirza S, Ruff P, Penny C (2024) Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges. Front Mol Biosci 11(September):1\u201323","journal-title":"Front Mol Biosci"},{"key":"1997_CR104","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/IJN.S429279","volume":"20","author":"A Ullah","year":"2025","unstructured":"Ullah A, Khan M, Zhang Y, Shafiq M, Ullah M, Abbas A, Xianxiang X, Chen G, Diao Y (2025) Advancing therapeutic strategies with polymeric drug conjugates for nucleic acid delivery and treatment. Int J Nanomedicine 20:25\u201352. https:\/\/doi.org\/10.2147\/IJN.S429279","journal-title":"Int J Nanomedicine"},{"issue":"5","key":"1997_CR105","doi-asserted-by":"publisher","first-page":"e2100639","DOI":"10.1002\/adhm.202100639","volume":"11","author":"L van der Koog","year":"2022","unstructured":"van der Koog L, Gandek TB, Nagelkerke A (2022) Liposomes and extracellular vesicles as drug delivery systems: a comparison of composition, pharmacokinetics, and functionalization. Adv Healthc Mater. 11(5):e2100639. https:\/\/doi.org\/10.1002\/adhm.202100639","journal-title":"Adv Healthc Mater."},{"issue":"15","key":"1997_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153837","volume":"15","author":"RC Wang","year":"2023","unstructured":"Wang RC, Wang Z (2023) Precision medicine: disease subtyping and tailored treatment. Cancers (Basel) 15(15):3837. https:\/\/doi.org\/10.3390\/cancers15153837","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1997_CR107","doi-asserted-by":"publisher","DOI":"10.1186\/s13036-022-00298-5","volume":"16","author":"J Wang","year":"2022","unstructured":"Wang J, Li B, Qiu L, Qiao X, Yang H (2022a) Dendrimer-based drug delivery systems: history, challenges, and latest developments. J Biol Eng 16(1):18. https:\/\/doi.org\/10.1186\/s13036-022-00298-5","journal-title":"J Biol Eng"},{"key":"1997_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.719705","volume":"9","author":"C Wang","year":"2022","unstructured":"Wang C, Xia Q, Zhang Q, Qu Y, Su S, Cheng JKW, Hughes NW, Cong L (2022b) CRISPR-Cas12a system with synergistic phage recombination proteins for multiplex precision editing in human cells. Front Cell Dev Biol 9:719705. https:\/\/doi.org\/10.3389\/fcell.2021.719705","journal-title":"Front Cell Dev Biol"},{"key":"1997_CR109","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jep.2014.09.034","volume":"157","author":"XH Wu","year":"2014","unstructured":"Wu XH, Ruan JL, Zhang J, Wang SQ, Zhang YW (2014) Pallidifloside D, a saponin glycoside constituent from Smilax riparia, resist to hyperuricemia based on URAT1 and GLUT9 in hyperuricemic mice. J Ethnopharmacol 157:201\u2013205","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"1997_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-025-00779-z","volume":"11","author":"C Wu","year":"2025","unstructured":"Wu C, Zhang C, Jin S, Wang JJ, Dai A, Xu J, Zhang H, Yang X, He X, Yuan Q, Hu W, Xu Y, Wang M, Jiang Y, Yang D, Xu HE (2025) Molecular mechanisms of urate transport by the native human URAT1 and its inhibition by anti-gout drugs. Cell Discov 11(1):33. https:\/\/doi.org\/10.1038\/s41421-025-00779-z","journal-title":"Cell Discov"},{"key":"1997_CR111","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jep.2015.04.011","volume":"169","author":"Y Yang","year":"2015","unstructured":"Yang Y, Zhang DM, Liu JH, Hu LS, Xue QC, Ding XQ, Kong LD (2015) Wuling san protects kidney dysfunction by inhibiting renal TLR4\/MyD88 signaling and NLRP3 inflammasome activation in high fructose-induced hyperuricemic mice. J Ethnopharmacol 169:49\u201359","journal-title":"J Ethnopharmacol"},{"key":"1997_CR112","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8825387","volume":"2020","author":"D Yang","year":"2020","unstructured":"Yang D, Wang T, Long M, Li P (2020) Quercetin: its main pharmacological activity and potential application in clinical medicine. Oxid Med Cell Longev 2020:8825387. https:\/\/doi.org\/10.1155\/2020\/8825387","journal-title":"Oxid Med Cell Longev"},{"key":"1997_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113308","volume":"143","author":"J Yang","year":"2024","unstructured":"Yang J, Jiang T, Lu X, li X, Zhou X, Guo X et al (2024a) METTL14 downregulates GLUT9 through m6A methylation and attenuates hyperuricemia-induced fibrosis in mouse renal tubular epithelial cells. Int Immunopharmacol 143:113308","journal-title":"Int Immunopharmacol"},{"key":"1997_CR114","doi-asserted-by":"publisher","first-page":"14668","DOI":"10.1021\/acs.jmedchem.4c01480","volume":"67","author":"X Yang","year":"2024","unstructured":"Yang X, Li Y, Pan S et al (2024b) Discovery of a potent and orally bioavailable Xan- thine oxidase\/urate transporter 1 dual inhibitor as a potential treatment for hyperuricemia and gout. J Med Chem 67:14668\u201314691","journal-title":"J Med Chem"},{"issue":"16","key":"1997_CR115","doi-asserted-by":"publisher","first-page":"14668","DOI":"10.1021\/acs.jmedchem.4c01480","volume":"67","author":"X Yang","year":"2024","unstructured":"Yang X, Li Y, Pan S, Ma F, Chen H, Deng J, Yue J, Gong Q, Zheng M, Zeng Y, Li J, Zhang Y, Wang X, Zhang X (2024c) Discovery of a potent and orally bioavailable xanthine oxidase\/urate transporter 1 dual inhibitor as a potential treatment for hyperuricemia and gout. J Med Chem 67(16):14668\u201314691. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01480","journal-title":"J Med Chem"},{"issue":"5","key":"1997_CR116","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/cpt.1098","volume":"104","author":"SW Yee","year":"2018","unstructured":"Yee SW, Brackman DJ, Ennis EA, Sugiyama Y, Kamdem LK, Blanchard R, Galetin A, Zhang L, Giacomini KM (2018) Influence of transporter polymorphisms on drug disposition and response: a perspective from the International Transporter Consortium. Clin Pharmacol Ther 104(5):803\u2013817. https:\/\/doi.org\/10.1002\/cpt.1098","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1997_CR117","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1208\/s12249-017-0905-z","volume":"19","author":"YF Yin","year":"2018","unstructured":"Yin YF, Guo Y, Song WD, Duan XC, Zheng XC, Zhong T, Zhang S, Yao X, Xu MQ, Zhang Q, Zhang X (2018) Improving solubility and oral bioavailability of Febuxostat by polymer-coated nanomatrix. AAPS PharmSciTech 19(2):934\u2013940. https:\/\/doi.org\/10.1208\/s12249-017-0905-z","journal-title":"AAPS PharmSciTech"},{"key":"1997_CR118","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/jsfa.10745","volume":"101","author":"Z Yu","year":"2021","unstructured":"Yu Z, Kan R, Wu S, Guo H, Zhao W, Ding L et al (2021) Xanthine oxidase inhibitory peptides derived from tuna protein: virtual screening, inhibitory activity, and molecular mechanisms. J Sci Food Agric 101:1349\u20131354. https:\/\/doi.org\/10.1002\/jsfa.10745","journal-title":"J Sci Food Agric"},{"key":"1997_CR119","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1210\/jc.2015-2527","volume":"100","author":"H Yuan","year":"2015","unstructured":"Yuan H, Yu C, Li X, Sun L, Zhu X, Zhao C, Zhang Z, Yang Z (2015) Serum uric acid levels and risk of metabolic syndrome: a dose-response meta-analysis of prospective studies. J Clin Endocrinol Metab 100:4198\u20134207","journal-title":"J Clin Endocrinol Metab"},{"key":"1997_CR120","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5419890","volume":"2022","author":"Q Yuan","year":"2022","unstructured":"Yuan Q, Cheng Y, Sheng R, Yuan Y, Hu M (2022) A brief review of natural products with urate transporter 1 inhibition for the treatment of hyperuricemia. Evid Based Complement Alternat Med 2022:5419890. https:\/\/doi.org\/10.1155\/2022\/5419890","journal-title":"Evid Based Complement Alternat Med"},{"key":"1997_CR121","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2021.12203","volume":"24","author":"X Zhang","year":"2021","unstructured":"Zhang X, Nie Q, Zhang Z, Zhao J, Zhang F, Wang C, Wang X, Song G (2021) Resveratrol affects the expression of uric acid transporter by improving inflammation. Mol Med Rep 24:564","journal-title":"Mol Med Rep"},{"issue":"17","key":"1997_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/nu14173525","volume":"26","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Chen S, Yuan M, Xu Y, Xu H (2022a) Gout and diet: a comprehensive review of mechanisms and management. Nutrients 26(17):3525. https:\/\/doi.org\/10.3390\/nu14173525","journal-title":"Nutrients"},{"key":"1997_CR123","doi-asserted-by":"publisher","first-page":"114816","DOI":"10.1016\/j.ejmech.2022.114816","volume":"244","author":"J Zhang","year":"2022","unstructured":"Zhang J, Dong Y, Gao S, Zhang X, Liao H, Shi X (2022) Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors. Eur J Med Chem 244:114816. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0223523422007188","journal-title":"Eur J Med Chem"},{"issue":"1","key":"1997_CR124","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41401-021-00640-5","volume":"43","author":"ZA Zhao","year":"2022","unstructured":"Zhao ZA, Jiang Y, Chen YY, Wu T, Lan QS, Li YM, Li L, Yang Y, Lin CT, Cao Y, Zhou PZ, Guo JY, Tian YX, Pang JX (2022a) CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia. Acta Pharmacol Sin 43(1):121\u2013132. https:\/\/doi.org\/10.1038\/s41401-021-00640-5","journal-title":"Acta Pharmacol Sin"},{"key":"1997_CR125","doi-asserted-by":"publisher","first-page":"114682","DOI":"10.1016\/j.ejmech.2022.114682","volume":"242","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Liu J, Yuan L, Yang Z, Kuang P, Liao H (2022) Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents. Eur J Med Chem 242:114682. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0223523422005840","journal-title":"Eur J Med Chem"},{"issue":"26","key":"1997_CR126","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1089\/gtmb.2021.0175","volume":"1","author":"Q Zheng","year":"2022","unstructured":"Zheng Q, Keliang W, Hongtao Q, Xiaosheng L (2022) Genetic association between SLC22A12 variants and susceptibility to hyperuricemia: a meta-analysis. Genet Test Mol Biomarkers 1(26):81\u201395","journal-title":"Genet Test Mol Biomarkers"},{"key":"1997_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2012.00234","volume":"3","author":"J Zhou","year":"2012","unstructured":"Zhou J, Bobbin ML, Burnett JC, Rossi JJ (2012) Current progress of RNA aptamer-based therapeutics. Front Genet 3:234. https:\/\/doi.org\/10.3389\/fgene.2012.00234","journal-title":"Front Genet"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01997-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01997-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01997-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T20:05:33Z","timestamp":1763409933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01997-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":127,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1997"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01997-3","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declared no conflict of ineptest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}